Cadrenal Therapeutics, Inc. (CVKD)

NASDAQ: CVKD · IEX Real-Time Price · USD
0.610
-0.027 (-4.21%)
At close: Mar 28, 2024, 4:00 PM
0.640
+0.030 (4.92%)
After-hours: Mar 28, 2024, 7:43 PM EDT

Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.

The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics logo
Country United States
Founded 2022
IPO Date Jan 20, 2023
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Quang X. Pham

Contact Details

Address:
822 A1a North, Suite 300
Ponte Vedra, Florida 32082
United States
Phone 904-300-0701
Website cadrenal.com

Stock Details

Ticker Symbol CVKD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.00
CIK Code 0001937993
ISIN Number US1276361086
Employer ID 88-0860746
SIC Code 2834

Key Executives

Name Position
Dr. Douglas W. Losordo FACC, FAHA, M.D. Chief Medical Officer
Quang X. Pham Chairman and Chief Executive Officer
Matthew K. Szot CPA, CPA Chief Financial Officer
Jeffrey Cole Chief Operating Officer

Latest SEC Filings

Date Type Title
Mar 20, 2024 EFFECT Notice of Effectiveness
Mar 12, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 12, 2024 S-3 Registration statement under Securities Act of 1933
Mar 12, 2024 8-K Current Report
Mar 11, 2024 8-K Current Report
Mar 11, 2024 10-K Annual Report
Mar 5, 2024 8-K Current Report
Feb 15, 2024 8-K/A [Amend] Current report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals